Central interleukin-1β-induced inhibition of acid secretion in rats: Specificity of action

doi:10.1016/0024-3205(93)90076-F

Life Sciences

Volume 52, Issue 9, 1993, Pages 785-792

https://doi.org/10.1016/0024-3205(93)90076-F Get rights and content

Abstract

It is well established that IL-1β acts in the brain to potently inhibit gastric acid secretion in pylorusligated rats. The present study was designed to further investigate the specificity and mechanisms of the centrally mediated antisecretory action of IL-1β in conscious rats. Intracerebroventricular injection of IL-1β (100 ng) decreased acid secretion in pylorus-ligated rats and inhibited basal and pentagastrin-stimulated acid secretion in rats with chronic gastric fistula. The antisecretory effect of IL-1β (100 ng) injected into the lateral ventricle of pylorus ligated rats was completely reversed by prior intracerebroventricular injection of the IL-1 receptor antagonist, IL-1ra, (100 μg). Peripheral administration of the somatostatin monoclonal antibody, CURE.S6, did not modify intracisternal IL-1β-induced inhibition of acid secretion in pylorus ligated rats. IL-6 and tumor necrosis factor-α (100 ng) injected intracisternally did not influence gastric acid secretion in pylorus-ligated rats. These data show that IL-1β action in the CNS is mediated through interaction with specific IL-1 receptors and is selective to this cytokine. IL-1β antisecretory action can be observed under basal and pentagastrin-stimulated conditions and is independent from somatostatin release in the periphery.

References (36)

R.M. Lechan et al.
Brain Res.
(1990)
G. Katsuura et al.
Biochem. Biophys. Res. Commun.
(1988)
N.J. Rothwell
Trends Pharmacol. Sci.
(1991)
E. Saperas et al.
Eur. J. Pharmacol.
(1991)
E. Barocelli et al.
Gastroenterology
(1991)
R.L. Stephens et al.
Peptides
(1988)
E. Saperas et al.
Gastroenterology
(1990)
A. Uehara et al.
Biochem. Biophys. Res. Commun.
(1989)
T. Ishikawa et al.
Neurosci. Lett.
(1990)
C.A. Dinarello et al.
Immunol. Today
(1991)

H. Nishikawa et al.

Jpn. J. Pharmacol.

(1987)

H. Yang et al.

Gastroenterology

(1990)

H.C. Wong et al.

Peptides

(1990)

A. Uehara et al.

Biochem. Biophys. Res. Commun.

(1990)

E. Saperas et al.

Peptides

(1992)

F. Coceani et al.

Brain Res.

(1988)

G.A. Higgins et al.

Mol. Brain Res.

(1991)

G. Ju et al.

Neurosci. Lett.

(1991)

Cited by (16)

IL1B promoter polymorphism regulates the expression of gastric acid stimulating hormone gastrin
2009, International Journal of Biochemistry and Cell Biology
It is important to dissect the effect of the alternative alleles of a functional SNP on the entire biochemical pathway for the complete understanding of the mechanism of the manifestation of complex diseases. IL1B-511C > T and -31C > T promoter polymorphisms have been suggested as potential susceptibility loci for Helicobacter pylori associated gastroduodenal diseases. We report that altered expression of IL1B due to a specific polymorphism in its promoter modulates the expression of gastrin, an acid regulating hormone. Treatment of gastric carcinoma cells, AGS, with IL1B resulted in a 20-fold reduction in gastrin expression. Gastrin promoter assay showed that IL1B inhibits gastrin expression at the transcriptional level and part of this inhibitory process is mediated via activation of NFκB and involvement of HDACs. An almost 3-fold increase in IL1B expression was observed when AGS cells were transfected with -31TIL1B expression plasmid in comparison to -31CIL1B. The -31TIL1B induced a 2-fold greater repression of the gastrin luciferase activity compared to -31CIL1B. This signaling of the -31TIL1B variant allele driven IL1B revealed an almost 1.5-fold greater expression of NFκB. Thus, this study showed that a single base substitution at the -31 position of the IL1B promoter brought about differential expression of IL1B which differentially altered both NFκB activation and gastrin expression.
Histamine H<inf>3</inf> receptors and gastric acid secretion [5] (multiple letters)
1998, Gastroenterology
Somatostatin antibody does not influence bombesin-induced inhibition of gastric acid secretion in rats
1995, Peptides
The influence of peripheral somatostatin immunoneutralization on intravenous (IV) and intracerebroventricular (ICV) bombesin-induced inhibition of gastric acid secretion (GAS) was investigated with the somatostatin monoclonal antibody, CURE.S6, in rats. The somatostatin antibody, injected IV in conscious rats with a chronic gastric fistula and IV catheter, did not modify basal GAS, whereas in urethane-anesthetized rats the basal GAS was increased by 150%. In conscious rats, somatostatin (15 μg/kg/h, IV) inhibited basal GAS by 50% after injection of control antibody but not after pretreatment with the somatostatin antibody. With pretreatment with a control antibody, bombesin (10 μg/kg/h, IV) inhibited basal GAS by 60% in conscious rats and by 50% the acid response to pentagastrin infusion in urethane-anesthetized rats. Bombesin injected ICV (3 and 10 ng/10 μl/rat) inhibited basal GAS by 50% and 70%, respectively, in conscious rats pretreated with a control antibody. The somatostatin antibody injected IV before IV or ICV injection of bombesin did not influence bombesin-induced inhibition of GAS in conscious or anesthetized rats. These results show that peripheral somatostatin does not play a major role in the inhibition of gastric acid secretion induced either by ICV or IV administration of bombesin or basal acid secretion in conscious rats.
Interleukin 1β inhibits gastric emptying in rats: Mediation through prostaglandin and corticotropin-releasing factor
1994, Gastroenterology
Background/Aims: Interleukin 1β (IL-1β) increases the release of corticotropin-releasing factor (CRF) in the brain through prostaglandin pathways. Because central CRF inhibits gastric motor function, the influence and mechanism of action of intracisternal injection of IL-1β on gastric emptying were investigated. Methods: The 20-minute rate of gastric emptying of a nonnutrient test meal was assessed by the phenol red methylcellulose method 30 minutes after injection of human recombinant IL-1β in conscious rats. Results: IL-1β injected intracisternally (0.01–1 ng) or intravenously (0.01–10 ng) dose-dependently decreased gastric emptying by 10%–82% and 0%–89%, respectively. The median effective dose (ED₅₀) was 30-fold lower when IL-1β was injected intracisternally (0.1 ng) than intravenously (3 ng). The inhibitory effect of intracisternal IL-1β had a rapid onset (within 20 minutes) and was long-lasting (6 hours). Indomethacin (5 mg/kg, intraperitoneally) completely prevented the 61% inhibition induced by intracisternal IL-1β (0.1 ng) but had no effect on CRF-induced (600 ng) 72% inhibition of gastric emptying. The intracisternal injection of the IL-1 receptor antagonist (100 ng) or the CRF antagonist [DPhe¹², Nle^21,38,C^αMeLeu³⁷]CRF_12–41 (20 μg) prevented by 100% and 52%, respectively, the inhibition of gastric emptying evoked by intracisternal IL-1β (0.1 ng). The antagonists alone had no effect on basal gastric emptying. Conclusions: IL-1β acts in the brain to induce a long-lasting inhibition of gastric emptying; IL-1β action is mediated through central IL-1 receptors and prostaglandin- and CRF-dependent mechanisms.
Central Actions of Interleukin 1 on Gastrointestinal Function
1993, Methods in Neurosciences
This chapter discusses the central actions of interleukin 1 (IL-1) on gastrointestinal function. Several cytokines, including the polypeptide IL-1, are synthesized and produced by effector cells of the immune system during inflammation and injury. IL-1β is a constitutive component of the neural system, with a specific distribution in association with IL-1β receptors. The centrally mediated effects of IL-1β include—analgesia, anorexia, astrocyte growth, slow-wave sleep, thermogenesis, immunosuppression, hypothalamic release of somatostatin, brain noradrenergic activation, pituitary secretion of adreno-corticotropic hormone and prolactin, elevation of circulating insulin, catecholamine, corticosterone, IL-6, and inhibition of reproductive function. Many of these responses are mediated through the release of corticotropin-releasing factor and/or prostaglandins. IL-1 triggers a physiological stress response during immune recognition of an infectious agent. IL-1 acts in the central nervous system to inhibit gastric secretion, ulcer formation, and gastric and small intestinal motor activity, while stimulating colonic motor function. IL-1β in the brain plays a role in linking the interaction between the neuroimmune and neurogastrointestinal systems.
The role of interleukin-1 and associated cytokines in gastric carcinogenesis
2012, Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

View all citing articles on Scopus

View full text

Central interleukin-1β-induced inhibition of acid secretion in rats: Specificity of action

Abstract

Brain Res.

Biochem. Biophys. Res. Commun.

Trends Pharmacol. Sci.

Eur. J. Pharmacol.

Gastroenterology

Peptides

Gastroenterology

Biochem. Biophys. Res. Commun.

Neurosci. Lett.

Immunol. Today

Jpn. J. Pharmacol.

Gastroenterology

Peptides

Biochem. Biophys. Res. Commun.

Peptides

Brain Res.

Mol. Brain Res.

Neurosci. Lett.